HemaCare’s Losses Widen With AIDS Research Costs

HemaCare Corp., a Sherman Oaks provider of blood-related products and services, saw its losses widen in the second quarter and six months that ended June 30, partially a result of research and development expenses for the company’s experimental AIDS therapy.

HemaCare lost $763,089 in the latest three-month period, in contrast with a $657,800 loss a year before. Its second-quarter revenue was $2.81 million, up 2% from $2.75 million in revenue in the second quarter of 1992.

For the six months, the company’s loss was $1.23 million, while its revenue totaled $6.14 million, a 4% gain. A year earlier, HemaCare lost $636,413 on $5.93 million in revenue.

HemaCare also said its core business has been hurt by continuing downward pressure on health-care utilization and the sluggish Southern California economy.